Protein Allergy Clinical Trial
Official title:
Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Cow's Milk Hypersensitivity
Cow Milk Allergy (CMA) occurs in 2 to 5 % of all infants. Reflux, regurgitation and vomiting
are well recognised symptoms of CMA. The recommended treatment of CMA is an extensive
hydrolysate. The North American Society of Pediatric Gastroenterology Hepatology and
Nutrition (NASPGHAN) & the European Society of Pediatric Gastroenterology Hepatology and
Nutrition (ESPGHAN) reflux guidelines have no strict recommendations for the treatment of
distressed infants with reflux, suspected of CMA. One of the preferred proposed options is
to thicken an extensive hydrolysate .
This study aims at evaluating the additional value of a thickened extensive hydrolysate in
children suspected of CMA and presenting with frequent regurgitation.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01998074 -
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
|
N/A |